Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,139,689
  • Shares Outstanding, K 74,762
  • Annual Sales, $ 772,600 K
  • Annual Income, $ 131,100 K
  • 36-Month Beta 0.58
  • Price/Sales 2.77
  • Price/Cash Flow 14.43
  • Price/Book 1.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.34
  • Number of Estimates 4
  • High Estimate 0.39
  • Low Estimate 0.31
  • Prior Year 0.31
  • Growth Rate Est. (year over year) +9.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.80 +10.71%
on 12/24/18
32.41 -8.45%
on 01/04/19
+0.17 (+0.58%)
since 12/18/18
3-Month
26.80 +10.71%
on 12/24/18
46.76 -36.55%
on 10/31/18
-14.92 (-33.46%)
since 10/18/18
52-Week
26.80 +10.71%
on 12/24/18
50.44 -41.18%
on 09/04/18
-8.32 (-21.90%)
since 01/18/18

Most Recent Stories

More News
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.

AMED : 127.12 (+0.18%)
ILMN : 312.75 (+0.87%)
MYGN : 29.67 (+3.67%)
VEEV : 106.03 (+2.49%)
Myriad Genetics Shares Down 31.8% Since SmarTrend's Sell Call (MYGN)

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on October 8th, 2018 at $42.84. In approximately 3 months, Myriad Genetics has returned 31.81% as of today's recent price of $29.21.

MYGN : 29.67 (+3.67%)
MYGN vs. SWTUY: Which Stock Should Value Investors Buy Now?

MYGN vs. SWTUY: Which Stock Is the Better Value Option?

MYGN : 29.67 (+3.67%)
SWTUY : 25.2900 (+11.56%)
Has Myriad Genetics (MYGN) Outpaced Other Medical Stocks This Year?

Is (MYGN) Outperforming Other Medical Stocks This Year?

MYGN : 29.67 (+3.67%)
Myriad Genetics Down 33.8% Since SmarTrend Downtrend Call (MYGN)

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on October 8th, 2018 at $42.84. In approximately 3 months, Myriad Genetics has returned 33.82% as of today's recent price of $28.35.

MYGN : 29.67 (+3.67%)
Epizyme to File NDA for Tazemetostat in Follicular Lymphoma

Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.

CELG : 86.27 (-0.37%)
MYGN : 29.67 (+3.67%)
RHHBY : 32.6100 (+0.59%)
EPZM : 9.56 (unch)
Aerie's Rhopressa Succeeds in Study on Japanese Patients

Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.

AERI : 43.99 (+2.71%)
MYGN : 29.67 (+3.67%)
EDIT : 26.14 (-0.27%)
PFE : 42.53 (+0.14%)
Why the Earnings Surprise Streak Could Continue for Myriad (MYGN)

Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MYGN : 29.67 (+3.67%)
Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%

Myriad Genetics (MYGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

MYGN : 29.67 (+3.67%)
ACOR : 16.26 (-3.73%)
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics

Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.

JAZZ : 129.07 (+1.32%)
MYGN : 29.67 (+3.67%)
EDIT : 26.14 (-0.27%)
INO : 5.09 (+0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade MYGN with:

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

2nd Resistance Point 30.36
1st Resistance Point 30.01
Last Price 29.67
1st Support Level 29.02
2nd Support Level 28.38

See More

52-Week High 50.44
Fibonacci 61.8% 41.41
Fibonacci 50% 38.62
Fibonacci 38.2% 35.83
Last Price 29.67
52-Week Low 26.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar